First-Generation COVID-19 vaccine program, CVnCoV
Phase 3 trial started with CVnCoV in adults suffering from selected comorbidities
Phase 2a trial in Peru and Panama assessing third booster vaccination at one and six month post second dose
CureVac participating in broad UK trial evaluating different COVID-19 vaccines as potential boosters at least three months following full primary vaccination
First preclinical data of second-generation COVID-19 vaccine candidate, CV2CoV, demonstrates faster onset of antibody production and high variant cross-neutralization
Rolling submission with Swissmedic initiated after filing of first data package
Financials: cash position of €1.50 billion as of March 31, 2021
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.